New Study Shows Pfizer COVID-19 Pill Provides “No Significant Benefit” For Individuals Under Age 65
Israeli scientists analyzed data provided by a major healthcare provider in the country, Clalit Health Services, covering 109,213 individuals who had eligibility to receive Pfizer’s Nirmatrelvir pill, also known by the name Paxlovid,!-->…